Free Trial

InMode (INMD) Competitors

InMode logo
$13.56 +0.06 (+0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$13.56 -0.01 (-0.04%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INMD vs. MMED, WRBY, TMDX, LMAT, and AXGN

Should you buy InMode stock or one of its competitors? MarketBeat compares InMode with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMode include MiniMed Group (MMED), Warby Parker (WRBY), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

How does InMode compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and InMode (NASDAQ:INMD) are both medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, MiniMed Group had 6 more articles in the media than InMode. MarketBeat recorded 9 mentions for MiniMed Group and 3 mentions for InMode. InMode's average media sentiment score of 0.63 beat MiniMed Group's score of -0.04 indicating that InMode is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
InMode
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InMode has a net margin of 23.27% compared to MiniMed Group's net margin of 0.00%. InMode's return on equity of 13.47% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
InMode 23.27%13.47%11.95%

InMode has lower revenue, but higher earnings than MiniMed Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$2.99B1.42N/AN/AN/A
InMode$370.49M2.32$93.83M$1.369.97

19.7% of MiniMed Group shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MiniMed Group currently has a consensus target price of $21.33, indicating a potential upside of 41.09%. InMode has a consensus target price of $16.00, indicating a potential upside of 17.99%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than InMode.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73
InMode
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

InMode beats MiniMed Group on 7 of the 12 factors compared between the two stocks.

How does InMode compare to Warby Parker?

InMode (NASDAQ:INMD) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

68.0% of InMode shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InMode has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 17.99%. Warby Parker has a consensus price target of $29.50, indicating a potential upside of 18.09%. Given Warby Parker's stronger consensus rating and higher probable upside, analysts plainly believe Warby Parker is more favorable than InMode.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Warby Parker
0 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.64

In the previous week, InMode had 2 more articles in the media than Warby Parker. MarketBeat recorded 3 mentions for InMode and 1 mentions for Warby Parker. Warby Parker's average media sentiment score of 1.79 beat InMode's score of 0.63 indicating that Warby Parker is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InMode
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Warby Parker
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

InMode has a net margin of 23.27% compared to Warby Parker's net margin of 0.15%. InMode's return on equity of 13.47% beat Warby Parker's return on equity.

Company Net Margins Return on Equity Return on Assets
InMode23.27% 13.47% 11.95%
Warby Parker 0.15%2.30%1.18%

InMode has higher earnings, but lower revenue than Warby Parker. InMode is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$370.49M2.32$93.83M$1.369.97
Warby Parker$871.91M3.07$1.64M$0.021,249.05

Summary

Warby Parker beats InMode on 10 of the 16 factors compared between the two stocks.

How does InMode compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$605.49M4.24$190.29M$4.4016.88
InMode$370.49M2.32$93.83M$1.369.97

TransMedics Group currently has a consensus target price of $134.00, indicating a potential upside of 80.37%. InMode has a consensus target price of $16.00, indicating a potential upside of 17.99%. Given TransMedics Group's stronger consensus rating and higher probable upside, research analysts plainly believe TransMedics Group is more favorable than InMode.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.46
InMode
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, TransMedics Group had 3 more articles in the media than InMode. MarketBeat recorded 6 mentions for TransMedics Group and 3 mentions for InMode. TransMedics Group's average media sentiment score of 0.67 beat InMode's score of 0.63 indicating that TransMedics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InMode
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

TransMedics Group has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, InMode has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to InMode's net margin of 23.27%. TransMedics Group's return on equity of 22.38% beat InMode's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group27.04% 22.38% 8.46%
InMode 23.27%13.47%11.95%

Summary

TransMedics Group beats InMode on 13 of the 16 factors compared between the two stocks.

How does InMode compare to LeMaitre Vascular?

InMode (NASDAQ:INMD) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 17.99%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 16.58%. Given InMode's higher possible upside, equities analysts plainly believe InMode is more favorable than LeMaitre Vascular.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
LeMaitre Vascular
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

InMode has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

68.0% of InMode shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, LeMaitre Vascular had 1 more articles in the media than InMode. MarketBeat recorded 4 mentions for LeMaitre Vascular and 3 mentions for InMode. InMode's average media sentiment score of 0.63 beat LeMaitre Vascular's score of 0.54 indicating that InMode is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InMode
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LeMaitre Vascular
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

InMode has higher revenue and earnings than LeMaitre Vascular. InMode is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$370.49M2.32$93.83M$1.369.97
LeMaitre Vascular$249.60M8.84$57.73M$2.7135.64

LeMaitre Vascular has a net margin of 24.35% compared to InMode's net margin of 23.27%. LeMaitre Vascular's return on equity of 15.36% beat InMode's return on equity.

Company Net Margins Return on Equity Return on Assets
InMode23.27% 13.47% 11.95%
LeMaitre Vascular 24.35%15.36%9.78%

Summary

LeMaitre Vascular beats InMode on 11 of the 17 factors compared between the two stocks.

How does InMode compare to AxoGen?

AxoGen (NASDAQ:AXGN) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

InMode has a net margin of 23.27% compared to AxoGen's net margin of -13.21%. InMode's return on equity of 13.47% beat AxoGen's return on equity.

Company Net Margins Return on Equity Return on Assets
AxoGen-13.21% -9.63% -6.26%
InMode 23.27%13.47%11.95%

AxoGen currently has a consensus target price of $46.50, indicating a potential upside of 8.47%. InMode has a consensus target price of $16.00, indicating a potential upside of 17.99%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than AxoGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
InMode
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, InMode has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

In the previous week, AxoGen had 1 more articles in the media than InMode. MarketBeat recorded 4 mentions for AxoGen and 3 mentions for InMode. AxoGen's average media sentiment score of 0.67 beat InMode's score of 0.63 indicating that AxoGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AxoGen
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
InMode
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$225.21M10.12-$15.70M-$0.64N/A
InMode$370.49M2.32$93.83M$1.369.97

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

InMode beats AxoGen on 10 of the 16 factors compared between the two stocks.

Get InMode News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INMD vs. The Competition

MetricInModeMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$855.34M$8.37B$6.68B$11.95B
Dividend YieldN/A2.52%2.67%5.58%
P/E Ratio9.9716.3724.5623.76
Price / Sales2.325.64566.69129.97
Price / Cash9.0517.4526.9937.23
Price / Book1.263.5910.526.75
Net Income$93.83M$225.32M$3.56B$337.35M
7 Day Performance0.44%1.19%-1.11%-2.54%
1 Month Performance-2.87%2.78%1.28%1.42%
1 Year Performance-6.87%-2.84%21.20%24.71%

InMode Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INMD
InMode
2.4083 of 5 stars
$13.56
+0.4%
$16.00
+18.0%
-4.7%$855.34M$370.49M9.97480
MMED
MiniMed Group
4.1241 of 5 stars
$12.00
-0.3%
$21.67
+80.6%
N/A$3.37B$2.99BN/A8,000
WRBY
Warby Parker
4.1308 of 5 stars
$24.43
-0.4%
$29.50
+20.8%
+8.7%$2.63B$871.91M1,222.114,036
TMDX
TransMedics Group
4.6702 of 5 stars
$67.53
+0.5%
$134.00
+98.4%
-48.8%$2.32B$605.49M15.35210
LMAT
LeMaitre Vascular
4.4969 of 5 stars
$91.42
-3.4%
$112.60
+23.2%
+13.1%$2.16B$249.60M33.73490

Related Companies and Tools


This page (NASDAQ:INMD) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners